Anzeige
Mehr »
Login
Freitag, 19.04.2024 Börsentäglich über 12.000 News von 689 internationalen Medien
Goldaktie: Eine Erfolgsgeschichte, die seinesgleichen sucht, startet gerade richtig durch!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
Dow Jones News
659 Leser
Artikel bewerten:
(2)

AlzChem's starting material for Creapure(R) notified in the USA as 'generally safe for use in food' - an important prerequisite for the continuation of the international success story of Creapure(R)

DJ AlzChem's starting material for Creapure(R) notified in the USA as 'generally safe for use in food' - an important prerequisite for the continuation of the international success story of Creapure(R)

DGAP-Media / 2021-01-22 / 13:48 
AlzChem, the leading manufacturer of high-quality creatine monohydrate, has successfully presented in a voluntary GRAS 
notification that the use of its self-manufactured creatine monohydrate under the Creapure^(R) brand in food is safe. 
GRAS stands for "Generally Recognized As Safe". The conclusion is based on all available data on creatine in 
conjunction with the controlled manufacturing process and the high product quality of AlzChem's self-manufactured 
creatine monohydrate under the Creapure^(R) brand. 
In accordance with the standard procedure for GRAS notification, AlzChem had submitted extensive documentation and 
evaluation of the freely available scientific information as well as the closely controlled manufacturing process. The 
formal review of the GRAS notification by the U.S. Food and Drug Administration (FDA) did not lead to any queries. As a 
result, AlzChem's self-manufactured creatine monohydrate can be safely used in food under the Creapure^(R) brand, for 
example in energy drinks, protein bars and powders, milkshakes, meal replacement powders and bars, meat replacement 
products and powdered drink mixes. 
As a leading manufacturer of high-quality creatine monohydrate, AlzChem continuously pursues the goal of making 
creatine and its positive effects widely available. The GRAS status of AlzChem's self-manufactured creatine monohydrate 
under the Creapure^(R) brand opens up new opportunities for its use, including in specialty foods to optimize the diets 
of vegetarians and vegans who do not consume creatine in their normal diets, as well as in functional foods that 
support healthy, active living and overall well-being. 
Creatine is a natural substance in the human body that plays a central role in energy metabolism within every single 
cell of the body - in skeletal muscles as well as in the heart, brain and other organs, and in immune cells. Creatine 
is partly produced in the human body itself or can be ingested through food. About 95 percent of creatine is located in 
muscles and the brain, where the largest amounts of energy are needed. A sufficiently high creatine store in the muscle 
cells increases both the performance and the endurance of the muscles. The same applies to the brain, which accounts 
for about 20 percent of the body's total energy consumption. Creatine occurs naturally in foods such as meat, fish and 
other animal products, while foods of plant origin do not contain creatine. 
About AlzChem 
AlzChem is a globally active specialty chemicals company that is predominantly one of the market leaders in its fields 
of activity. AlzChem benefits in a special way from the three very different global megatrends sustainability, 
population growth and healthy aging. AlzChem products offer attractive solutions in a variety of different 
applications. 
The company sees interesting growth prospects for itself especially in the areas of nutrition of humans and animals, 
pharmaceuticals, agriculture, fine chemicals, metallurgy and in renewable energies. The wide range of products 
includes, for example, food supplements, plant growth regulators and precursors for corona tests. 
The company employs around 1,620 people at four production sites in Germany and Sweden, as well as at two sales 
companies in the U.S. and China. In 2019, AlzChem generated consolidated sales of around EUR 376 million and EBITDA of 
around EUR 50 million. 
End of Media Release 
=---------------------------------------------------------------------------------------------------------------------- 
Issuer: AlzChem Group AG 
Key word(s): Health 
2021-01-22 Dissemination of a Press Release, transmitted by DGAP - a service of EQS Group AG. 
The issuer is solely responsible for the content of this announcement. 
The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. 
Archive at www.dgap.de 
=---------------------------------------------------------------------------------------------------------------------- 
Language:     English 
Company:      AlzChem Group AG 
              Dr.-Albert-Frank-Str. 32 
              83308 Trostberg 
              Germany 
Phone:        +498621862888 
Fax:          +49862186502888 
E-mail:       ir@alzchem.com 
Internet:     www.alzchem.com 
ISIN:         DE000A2YNT30 
WKN:          A2YNT3 
Listed:       Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Stuttgart 
EQS News ID:  1162281 
 
End of News    DGAP Media 
=--------- 

(MORE TO FOLLOW) Dow Jones Newswires

January 22, 2021 07:48 ET (12:48 GMT)

Großer Insider-Report 2024 von Dr. Dennis Riedl
Wenn Insider handeln, sollten Sie aufmerksam werden. In diesem kostenlosen Report erfahren Sie, welche Aktien Sie im Moment im Blick behalten und von welchen Sie lieber die Finger lassen sollten.
Hier klicken
© 2021 Dow Jones News
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.